Monte Rosa Therapeutics (GLUE) Accumulated Depreciation & Amortization (2023 - 2025)
Historic Accumulated Depreciation & Amortization for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $25.5 million.
- Monte Rosa Therapeutics' Accumulated Depreciation & Amortization rose 3944.49% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 3944.49%. This contributed to the annual value of $20.4 million for FY2024, which is 6631.82% up from last year.
- As of Q3 2025, Monte Rosa Therapeutics' Accumulated Depreciation & Amortization stood at $25.5 million, which was up 3944.49% from $23.4 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Accumulated Depreciation & Amortization peaked at $25.5 million during Q3 2025, and registered a low of $8.6 million during Q2 2023.
- For the 3-year period, Monte Rosa Therapeutics' Accumulated Depreciation & Amortization averaged around $16.6 million, with its median value being $16.2 million (2024).
- Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Accumulated Depreciation & Amortization showed a top increase of 8916.39% in 2024 and a maximum decrease of 1549.33% in 2024.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Accumulated Depreciation & Amortization stood at $12.2 million in 2023, then skyrocketed by 66.32% to $20.4 million in 2024, then grew by 25.34% to $25.5 million in 2025.
- Its Accumulated Depreciation & Amortization was $25.5 million in Q3 2025, compared to $23.4 million in Q2 2025 and $21.3 million in Q1 2025.